Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 Nov 16;5(11):e009333.
doi: 10.1136/bmjopen-2015-009333.

Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study

Derek J Ward  1 , Edward Hammond  1 , Luan Linden-Phillips  1 , Andrew J Stevens  2
Affiliations
Observational Study

Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study

Derek J Ward et al. BMJ Open. .

Abstract

Objectives: Recent decades have witnessed the development of highly innovative new antiviral drug therapies. However, there are concerns that rising costs and lengthening development times could have implications for future patient access to innovative new drugs. We sought to establish whether the time taken for the clinical development of new antiviral drugs launched in the UK had increased since the 1980s.

Design and setting: Retrospective observational study of all new antiviral drugs licensed for use in the UK.

Primary and secondary outcome measures: Duration of clinical development (from initiation of studies in humans to receipt of Marketing Authorisation), subdivided into clinical trial and regulatory approval periods by the date of Marketing Authorisation Application.

Results: 48 new antiviral drugs were licensed for use in the UK between 1981 and 2014 (inclusive), over half (54%) initially for HIV infection. The overall mean duration of clinical development was 77.2 months, of which 64.6 months was spent in clinical trials before regulatory submission. The total time in clinical development increased from 41.7 months for drugs licensed 1981-1992 to 91.7 months for drugs licensed 2004-2014. This increase was accounted for by an increase in the clinical trials period and not the regulatory approval period, for which there was no observable trend. Drugs initially licensed to treat hepatitis C had a longer duration of clinical development than those indicated for other viral infections. However, the, initially shorter clinical development durations of drugs indicated for HIV infection increased more rapidly across the study period than those indicated for other viral infections.

Conclusions: The time spent by antiviral drugs in clinical development has increased markedly in recent decades despite many initiatives to speed access to innovative new drugs. However, this represents only one part of the translational research pathway, and a complete picture of development timeframes is lacking.

Keywords: Drug development timeframes; Drug licensing; United Kingdom; Viral infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Duration of clinical development for antiviral drugs by year of first license in the UK, 1981–2014.
Figure 2
Figure 2
Duration of clinical development for antiviral drugs indicated for HIV and other viral infections by year of first license in the UK, 1981–2014.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Satcher D. Emerging infections: getting ahead of the curve. Emerg Infect Dis 1995;1:1–6. 10.3201/eid0101.950101 - DOI - PMC - PubMed
    1. Marston HD, Folkers GK, Morens DM et al. . Emerging viral diseases: confronting threats with new technologies. Sci Transl Med 2014;6:10 10.1126/scitranslmed.3009872 - DOI - PubMed
    1. Hogg R, Lima V, Sterne JA et al. . Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293–9. 10.1016/S0140-6736(08)61113-7 - DOI - PMC - PubMed
    1. Sheridan C. FDA approvals usher in the post-interferon era in HCV. Nat Biotechnol 2014;32:3–5. 10.1038/nbt0114-3 - DOI - PubMed
    1. House of Commons Select Committee on Health. The influence of the pharmaceutical industry. London: House of Commons, 2005.

Publication types

Substances

LinkOut - more resources